q4 adjusted non-gaap earnings per share $0.38 from continuing operations including items.
as a result of its remediation efforts, material weaknesses were remediated as of december 25, 2021.
impact of the omicron variant of covid-19 on the company's financial results in the quarter was significant.
as of december 25, 2021, co was in compliance with its financial covenants.
currently exploring the sale of its nutrimetics and nuvo businesses.
sees 2022 operating cash flow net of investing cash flow to be between $120 million and $160 million.
